Your browser doesn't support javascript.
loading
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Belizna, Cristina; Pregnolato, Francesca; Abad, Sebastien; Alijotas-Reig, Jaume; Amital, Howard; Amoura, Zahir; Andreoli, Laura; Andres, Emmanuel; Aouba, Achile; Apras Bilgen, Sule; Arnaud, Laurent; Bienvenu, Boris; Bitsadze, Viktoria; Blanco, Patrick; Blank, Miri; Borghi, Maria Orietta; Caligaro, Antonia; Candrea, Elisabeta; Canti, Valentina; Chiche, Laurent; Chretien, Jean Marie; Cohen Tervaert, Jan Willem; Damian, Laura; Delross, Teresa; Dernis, Emmanuelle; Devreese, Katrien; Djokovic, Aleksandra; Esteve-Valverde, Enrique; Favaro, Maria; Fassot, Céline; Ferrer-Oliveras, Raquel; Godon, Alban; Hamidou, Mohamed; Hasan, Milena; Henrion, Daniel; Imbert, Bernard; Jeandel, Pierre Yves; Jeannin, Pascale; Jego, Patrick; Jourde-Chiche, Noemie; Khizroeva, Jamilya; Lambotte, Olivier; Landron, Cédric; Latino, Jose Omar; Lazaro, Estibaliz; de Leeuw, Karina; Le Gallou, Thomas; Kiliç, Levent; Limper, Maarten; Loufrani, Laurent.
Afiliación
  • Belizna C; Vascular and Coagulation Department, University Hospital Angers, Angers, France; MITOVASC institute and CARFI facility, UMR CNRS 6015, INSERM U1083, University of Angers, Angers, France. Electronic address: cristina.belizna@wanadoo.fr.
  • Pregnolato F; Istituto Auxologico Italiano, IRCCS, Laboratory of Immunorheumatology, Milan, Italy.
  • Abad S; Department of Internal Medicine, Hospital Avicenne, Publique - Hôpitaux de Paris, University Paris 13, Bobigny, France.
  • Alijotas-Reig J; Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Medicine, Universitat Autonòma, Barcelona, Spain.
  • Amital H; The Zabludowicz Center for Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
  • Amoura Z; Internal Medicine Department 2, Pitié-Salpêtrière Hospital, French National Centre for Rare Systemic Diseases, AP-HP, Paris, France; Paris VI University, UPMC, Sorbonne Universities, Paris, France.
  • Andreoli L; Rheumatology and Clinical Immunology Unit, University of Brescia, Brescia, Italy.
  • Andres E; Internal Medicine Department, University Hospital Strasbourg, Strasbourg, France.
  • Aouba A; Department of Internal Medicine, Caen University Hospital, Caen, France; University of Normandy, Caen, France.
  • Apras Bilgen S; Internal Medicine Department, Hacettepe University, Ankara, Turkey.
  • Arnaud L; Rheumatology Department, University Hospital Strasbourg, Strasbourg, France.
  • Bienvenu B; Department of Internal Medicine, Saint Joseph Hospital, Marseille, France.
  • Bitsadze V; Department of Obstetrics and Gynecology, I.M. Sechenow First Moscow State Medical University, Moscow, Russia.
  • Blanco P; ImmunoConcEpT, CNRS-UMR 5164, University Bordeaux, Bordeaux, France; FHU ACRONIM, Bordeaux University Hospital, Place Amélie Raba Léon, 33076 Bordeaux, France.
  • Blank M; The Zabludowicz Center for Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
  • Borghi MO; Istituto Auxologico Italiano, IRCCS, Laboratory of Immunorheumatology, Milan, Italy.
  • Caligaro A; Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Candrea E; Department of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Canti V; Immunology, Rheumatology, Allergology and Rare Disease-IRCCS San Raffaele Hospital, Laboratory of Autoimmunity and vascular inflammation San Raffaele, Milan, Italy.
  • Chiche L; Department of Internal Medicine and Infectious Disease, Hôpital européen Marseille, Marseille, France.
  • Chretien JM; Research Department Unit, University Hospital Angers, Angers, France.
  • Cohen Tervaert JW; Nephrology Department, Maastricht University, Maastricht, the Netherlands; Rheumatology Department, Kaye Edmonton Clinic University of Alberta, Edmonton, Canada.
  • Damian L; Department of Rheumatology, County Emergency Hospital Cluj-Napoca, Cluj-Napoca, Romania.
  • Delross T; Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Dernis E; Rheumatology, Centre Hospitalier du Mans, 72037 Le Mans, France.
  • Devreese K; Coagulation Laboratory, Department of Clinical Biology, Immunology and Microbiology, Ghent University Hospital, Ghent, Belgium.
  • Djokovic A; Scientific Research Department, Internal Medicine-Rheumatology Bezhanijska Kosa, University Medical Center, Belgrade University, Belgrade, Serbia.
  • Esteve-Valverde E; Department of Internal Medicine. Althaia Healthcare Network of Manresa, Barcelona, Spain.
  • Favaro M; Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Fassot C; MITOVASC institute and CARFI facility, UMR CNRS 6015, INSERM U1083, University of Angers, Angers, France.
  • Ferrer-Oliveras R; Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Godon A; Departement of hematology et immunology, University Hospital Angers, Angers, France.
  • Hamidou M; Department of Internal Medicine, University Hospital Nantes, Nantes, France.
  • Hasan M; Cytometry and Biomarkers Unit of Technology and Service, Center for Translational Science, Institut Pasteur, 28, Rue Doct Roux, 75015 Paris, France.
  • Henrion D; MITOVASC institute and CARFI facility, UMR CNRS 6015, INSERM U1083, University of Angers, Angers, France.
  • Imbert B; Vascular Medicine Department, Grenoble University Hospital, Grenoble, France.
  • Jeandel PY; Department of Internal Medicine, Archet-1 Hospital, University of Nice-Sophia-Antipolis, 151 Route de Saint Antoine de Ginestière, 06202 Nice, France.
  • Jeannin P; Departement of hematology et immunology, University Hospital Angers, Angers, France.
  • Jego P; Department of Internal Medicine, University Hospital Rennes, Rennes, France.
  • Jourde-Chiche N; INSERM, UMR-S 1076, VRCM, Aix-Marseille University, Marseille, France; Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France.
  • Khizroeva J; Department of Obstetrics and Gynecology, I.M. Sechenow First Moscow State Medical University, Moscow, Russia.
  • Lambotte O; Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie clinique, F-94275 Le Kremlin-Bicêtre, France; UMR 1184, Université Paris Sud, F-94276 Le Kremlin-Bicêtre, France; INSERM, U1184, Immunology of Viral Infections and Autoimmune Diseases, F-94276 Le Kremlin-Bicêtr
  • Landron C; Department of Internal Medicine, University Hospital Poitiers, Poitiers, France.
  • Latino JO; Autoimmune and thrombophilic disorders Department, Hospital Carlos G. Durand, Buenos Aires, Argentina.
  • Lazaro E; Department of Internal Medicine, Haut-Lévêque Hospital, 33604 Pessac, France.
  • de Leeuw K; Department of Internal Medicine, Division of Clinical Immunology, University Hospital Groningen, Groningen, the Netherlands.
  • Le Gallou T; Department of Internal Medicine, University Hospital Rennes, Rennes, France.
  • Kiliç L; Internal Medicine Department, Hacettepe University, Ankara, Turkey.
  • Limper M; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Loufrani L; MITOVASC institute and CARFI facility, UMR CNRS 6015, INSERM U1083, University of Angers, Angers, France.
Autoimmun Rev ; 17(12): 1153-1168, 2018 Dec.
Article en En | MEDLINE | ID: mdl-30316994
The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombosis / Síndrome Antifosfolípido / Parto Obstétrico / Hidroxicloroquina Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Autoimmun Rev Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombosis / Síndrome Antifosfolípido / Parto Obstétrico / Hidroxicloroquina Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Autoimmun Rev Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos